Figure 4.

Effects of adoptively transferred T cells on myeloma development. Mice (5 per group) were challenged with tumor A cells, followed by intravenous infusion of 10⁷ splenocytes or purified CD4⁺ and CD8⁺ T cells from tumor-A surviving mice vaccinated with gp96BCD or naive Balb/c mice 7 days later. Shown are (A) tumor burdens and (B) survival of mice receiving different T cells; or (C) percentages of proliferating CD4⁺ and CD8⁺ T cells measured by CFSE dilution in the spleens or lymph nodes of mice receiving CFSE-labeled splenocytes from naive or gp96BCD-vaccinated mice. The error bars in panel A represent SD of 5 mice. Representative results of 1 of 3 independent experiments performed are shown. *P < .05; **P < .01 (compared with controls).